Form 8K Retension Pharmaceuticals For: 18 November
- Investing.com
Metrics to compare | RTSN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRTSNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.9x | 3.4x | −0.2x | |
PEG Ratio | - | −0.25 | 0.00 | |
Price/Book | −7.5x | 0.9x | 2.6x | |
Price / LTM Sales | - | 1.4x | 2.7x | |
Upside (Analyst Target) | 286.7% | 116.4% | 69.6% | |
Fair Value Upside | Unlock | 38.5% | 11.7% | Unlock |
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.